The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma

Oncology ◽  
2019 ◽  
Vol 97 (1) ◽  
pp. 7-17 ◽  
Author(s):  
Joanna Huszno ◽  
Zofia Kolosza ◽  
Jolanta Mrochem-Kwarciak ◽  
Tomasz Rutkowski ◽  
Krzysztof Skladowski
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio

scholarly journals Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma

2019 ◽  
Vol 50 (2) ◽  
pp. 214-220 ◽  
Author(s):  
Yoshiaki Yamamoto ◽  
Hideyasu Matsuyama ◽  
Hiroaki Matsumoto ◽  
Shigeru Sakano ◽  
Nakanori Fuji ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Lactate Dehydrogenase ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Japanese Patients ◽  
Disease Specific Survival ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio ◽  
Disease Specific

Abstract Background Nivolumab is a standard treatment for previously treated advanced renal-cell carcinoma. However, nivolumab is effective in only a limited number of patients; therefore, we evaluated the prognostic value of several biomarkers, including inflammation-based prognostic scores and changes in these scores following nivolumab treatment in Japanese patients with metastatic renal-cell carcinoma. Methods We retrospectively reviewed the medical records of 65 patients with previously treated metastatic renal-cell carcinoma and who received nivolumab. Inflammation-based prognostic scores, including neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, and Glasgow prognostic score before and 6 weeks after the treatment were recorded. Categorical variables influencing disease-specific survival were compared using Cox proportional-hazards regression models. Results Univariate analysis showed that Memorial Sloan-Kettering Cancer Center risk score (P = 0.0052), lactate dehydrogenase (P = 0.0266), lymphocyte/monocyte ratio (P = 0.0113), and platelet/lymphocyte ratio (P = 0.0017) had a significant effect on disease-specific survival. Multivariate analyses showed that platelet/lymphocyte ratio and lactate dehydrogenase were found to be independent prognostic factors for disease-specific survival (P = 0.0008, risk ratio (RR) = 7.95, 95% confidence interval, 2.16–51.64 and P = 0.0123, RR = 3.92, 95% confidence interval, 1.37–10.80, respectively). The combination of platelet/lymphocyte ratio and lactate dehydrogenase was the most significant prognostic biomarker in metastatic renal-cell carcinoma (P < 0.0001). Changes in lymphocyte/monocyte ratio and platelet/lymphocyte ratio in response to nivolumab were significant prognostic factors for disease-specific survival (P < 0.0001 and P = 0.0477, respectively). Conclusions The combination of platelet/lymphocyte ratio and lactate dehydrogenase may be a potential biomarker for estimating disease-specific survival in Japanese patients with metastatic renal-cell carcinoma treated by nivolumab.

Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib

2021 ◽  
pp. 030089162110339
Author(s):  
Elena Bolzacchini ◽  
Monica Giordano ◽  
Lorenza Bertù ◽  
Marco Bregni ◽  
Olga Nigro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Multivariate Analysis ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Clinical Data ◽  
Renal Cell ◽  
Prognostic Role ◽  
Lymphocyte Ratio ◽  
Poor Risk

Background: Hemochrome parameters at the diagnosis of metastatic renal cell carcinoma (mRCC) and the development of macrocytosis during sunitinib therapy are considered prognostic. Objective: To evaluate the prognostic role of hematologic parameters and macrocytosis in mRCC treated with sunitinib. Methods: We analyzed clinical data of 100 patients with mRCC treated with sunitinib as first-line therapy in a retrospective multicenter study. We calculated neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) at baseline and erythrocyte mean corpuscular volume (MCV) during therapy. We considered the following cutoffs: NLR >3, PLR >150, LMR <3, and MCV >100 fl. Clinical data histology, prior nephrectomy, Fuhrman grading, metastatic sites, Memorial Sloan-Kettering Cancer Center score, and Heng score were collected. Overall survival (OS) and progression-free survival (PFS) were calculated. Univariate and multivariate analysis using Cox regression model with time-dependent (macrocytosis) covariate were applied. Results: At the univariate analysis, low LMR was associated with shorter PFS and OS ( p = 0.02 and p = 0.06, respectively). High PLR was associated with worse PFS ( p = 0.005); median OS was 23 vs 28 months ( p = 0.13). At the multivariate analysis, poor risk (Heng score), low LMR, and high PLR were associated with shorter PFS (hazard ratio 7.1, 1.5, and 2, respectively); poor PS and poor risk (Heng score) were related to worst OS. Macrocytosis was observed in 26 patients and was not prognostic of survival. Conclusions: In our cohort of patients with mRCC treated with sunitinib, low LMR (>3) and high PLR (>150) were associated with shorter PFS. Macrocytosis was not prognostic.

scholarly journals The clinical and prognostic value of the neutrophil lymphocyte ratio, the platelet lymphocyte ratio and mean platelet volume in tinnitus patients

2021 ◽  
Vol 38 (3) ◽  
pp. 251-254
Author(s):  
Ayşe ÇEÇEN ◽  
Esra KAVAZ ◽  
Seda GÜN
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Neck Region ◽  
Pathology Report ◽  
Lower Lip ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

Approximately 15% of renal cell carcinomas metastasize to the head and neck region. Here in, we report a rare case report of a patient who underwent nephrectomy for renal cell carcinoma (RCC) ten years ago and presented with metastatic renal cell carcinoma on her lower lip. A 65-year-old woman presented with a rapidly growing mass on the lower lip. Pathology report resulted in renal cell carcinoma metastasis. Although metastatic renal cell carcinoma to the head and neck is uncommon, metastasis should be considered in the differential diagnosis of a rapidly growing vascular lesion in the head and neck area of patients with renal cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document